About this Research Topic
Congenital heart disease (CHD) is the most common congenital malformation in children. The incidence of CHD is about 8‰ in newborns worldwide. Although prenatal screening technology has been greatly improved in recent years, issues on CHD and other birth defects are still prominent. Pulmonary hypertension associated with congenital heart disease (PH-CHD) refers to the elevation of pulmonary arterial pressure due to a shunt of systemic-pulmonary circulation, belonging to the first category of pulmonary hypertension classification. It is a common type of pediatric pulmonary hypertension and significantly increases the mortality in children with CHD. Surgery is an essential treatment for CHD. Pulmonary arterial hypertension (PAH) could occur at various stages of CHD, and is a key factor in determining the indications and prognosis of CHD surgeries. To date, standardized treatment for PH-CHD remains controversial because of the complexity of underlying cardiac anatomy and physiology, with a multitude of regulatory mechanisms not being fully understood.
With the extensive applications of artificial intelligence algorithms, accurate diagnosis and evaluation of PH-CHD can be effectively implemented based on big data. By establishing the prediction model of perioperative complications, early prevention, early diagnosis and early treatment can be achieved, thus improving the clinical outcome. Currently, targeted drugs are the main drug therapy for PH-CHD. However, the experience is mostly based on the results of adult studies, and high-level evidence-based studies is urgently needed to guide the use of drugs in children. Pulmonary rehabilitation, cardiopulmonary exercise test and stem cell transplantation are new approaches to treat PH, providing new options for patients with refractory PH-CHD. Until now, various susceptibility genotypes of PH-CHD have been reported. It is increasingly significant to elucidate the specific mechanisms of gene modification and to explore the interaction between gene and environmental factors. Individualized treatment of PH-CHD based on genomics and epigenetics is expected to improve the survival and prognosis of patients.
The goal of this research topic is to shed light on the advances in the field of PH-CHD, including perioperative management, novel therapeutic approaches, molecular regulatory mechanism, and so on. This collection will address emerging issues in both clinical observations and basic researches, aiming to provide a comprehensive overview on how to consider precise individualized treatment of PH-CHD.
We welcome submissions of Original Articles, Review, Meta-analysis and Case Report, in the following subtopics, but not limited to:
• Strategies for perioperative protection of multiple organ function in patients with PH-CHD.
• Novel therapeutic approaches for PH-CHD (modified surgical techniques; new drug therapy; stem cell transplantation therapy; pulmonary rehabilitation; cardiopulmonary exercise test, etc.)
• Screening of novel biomarkers for PH-CHD clinical prognosis and postoperative complications.
• Construction of prediction model of postoperative complications and prognosis in patients with PH-CHD based on artificial intelligence algorithm.
• Molecular regulatory mechanisms of PH-CHD development.
• Individualized treatment strategies for PH-CHD based on multi-omics.
With the extensive applications of artificial intelligence algorithms, accurate diagnosis and evaluation of PH-CHD can be effectively implemented based on big data. By establishing the prediction model of perioperative complications, early prevention, early diagnosis and early treatment can be achieved, thus improving the clinical outcome. Currently, targeted drugs are the main drug therapy for PH-CHD. However, the experience is mostly based on the results of adult studies, and high-level evidence-based studies is urgently needed to guide the use of drugs in children. Pulmonary rehabilitation, cardiopulmonary exercise test and stem cell transplantation are new approaches to treat PH, providing new options for patients with refractory PH-CHD. Until now, various susceptibility genotypes of PH-CHD have been reported. It is increasingly significant to elucidate the specific mechanisms of gene modification and to explore the interaction between gene and environmental factors. Individualized treatment of PH-CHD based on genomics and epigenetics is expected to improve the survival and prognosis of patients.
The goal of this research topic is to shed light on the advances in the field of PH-CHD, including perioperative management, novel therapeutic approaches, molecular regulatory mechanism, and so on. This collection will address emerging issues in both clinical observations and basic researches, aiming to provide a comprehensive overview on how to consider precise individualized treatment of PH-CHD.
We welcome submissions of Original Articles, Review, Meta-analysis and Case Report, in the following subtopics, but not limited to:
• Strategies for perioperative protection of multiple organ function in patients with PH-CHD.
• Novel therapeutic approaches for PH-CHD (modified surgical techniques; new drug therapy; stem cell transplantation therapy; pulmonary rehabilitation; cardiopulmonary exercise test, etc.)
• Screening of novel biomarkers for PH-CHD clinical prognosis and postoperative complications.
• Construction of prediction model of postoperative complications and prognosis in patients with PH-CHD based on artificial intelligence algorithm.
• Molecular regulatory mechanisms of PH-CHD development.
• Individualized treatment strategies for PH-CHD based on multi-omics.
Keywords: Pulmonary hypertension, congenital heart disease, individualized treatment, prognosis, risk factors
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
